Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q3

Rhea-AI Summary

NU Skin Enterprises (NYSE: NUS) reported Q3 2025 revenue $364.2M, adjusted net income $17.1M, and adjusted EPS $0.34, compared with Stonegate estimates of $374.2M, $14.7M and $0.30. Results were within guidance: revenue at the low end and EPS at the high end. Rhyz revenue totaled $51.6M (Manufacturing $47.6M; Rhyz Other $4.0M). The core Nu Skin business posted a 70.5% gross margin and company selling expense fell to 35.8% (41.7% in core). Management flagged double-digit Latin America growth, sequential segment improvement, and narrowed Q4 and full‑year 2025 guidance while preserving a focus on margins. Cash balance stood at $251.7M. Prysm iO limited preview is planned in late 4Q25; India pre‑market activity starts in 4Q25 ahead of a 2026 launch.

Positive

• Adjusted EPS beat estimates by ~13%
• Gross margin at 70.5%
• Rhyz contributed $51.6M revenue
• Cash balance of $251.7M

Negative

• Revenue missed Stonegate estimate by $10.0M
• Top-line at the low end of guidance despite EPS strength

Dallas, Texas--(Newsfile Corp. - November 7, 2025) - NU Skin Enterprises Inc. (NYSE: NUS): Stonegate Capital Partners updates their coverage on NU Skin Enterprises Inc. (NYSE: NUS). NUS reported revenue, adj NI, and adj EPS of $364.2M, $17.1M, and $0.34, respectively. This compares to our estimates of $374.2M, $14.7M, and $0.30, respectively. These results were at the low end of revenue guidance and the high end of EPS guidance. Rhyz delivered $51.6M of revenue, including $47.6M from Manufacturing and $4.0M from Rhyz Other, while the Nu Skin business posted 70.5% gross margin and continued to benefit from disciplined spending as selling expense declined to 35.8% company-wide and 41.7% within the core business. Management highlighted double-digit growth in Latin America and sequential improvement across several reporting segments, noting that execution and efficiency drove EPS to the high end of the range despite a challenging macro environment. Despite a weaker than expected top line results, management remains focused on delivering on its strategic initiatives.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Revenue $364.2M and EPS $0.34 within guidance; gross margin 70.5% and selling expense 35.8%.
• Prysm iO limited preview in late 4Q25; India pre-market activities begin in 4Q25 ahead of a 2026 launch.
• Cash $251.7M; management narrowed Q4 and full-year 2025 guidance with continued margin focus.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273607

FAQ

What were NU Skin (NUS) Q3 2025 revenue and adjusted EPS?

NU Skin reported Q3 2025 revenue $364.2M and adjusted EPS $0.34.

How did NU Skin (NUS) Q3 2025 results compare to Stonegate estimates?

Revenue was $364.2M vs Stonegate $374.2M (below estimate) while adjusted EPS was $0.34 vs $0.30 (above estimate).

What did NU Skin report for Rhyz revenue in Q3 2025 (NUS)?

Rhyz delivered $51.6M in revenue, split $47.6M manufacturing and $4.0M Rhyz Other.

Did NU Skin (NUS) change guidance after Q3 2025 results?

Management narrowed Q4 and full‑year 2025 guidance while keeping margin focus.

What margin and expense metrics did NU Skin (NUS) report for Q3 2025?

The Nu Skin business posted a 70.5% gross margin and company selling expense declined to 35.8%.

What near‑term product and market milestones did NU Skin (NUS) announce?

A Prysm iO limited preview is planned in late 4Q25 and India pre‑market activities begin in 4Q25 ahead of a 2026 launch.